{"id":586311,"date":"2026-07-17T00:00:00","date_gmt":"2026-07-17T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/concim0004-2026-biopharma-atopic-dermatitis-atopic-eczema-geographic-focus-china-atopic-dermatitis-china-in-depth\/"},"modified":"2026-07-18T11:20:32","modified_gmt":"2026-07-18T11:20:32","slug":"concim0004-2026-biopharma-atopic-dermatitis-atopic-eczema-geographic-focus-china-atopic-dermatitis-china-in-depth","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/concim0004-2026-biopharma-atopic-dermatitis-atopic-eczema-geographic-focus-china-atopic-dermatitis-china-in-depth\/","title":{"rendered":"Atopic Dermatitis \/ Atopic Eczema &#8211; Geographic Focus: China &#8211; Atopic Dermatitis &#8211; China In-Depth (China)"},"content":{"rendered":"<p>China\u2019s atopic dermatitis (<abbr data-abbreviation-entity=\"7654\" title=\"atopic dermatitis\">AD<\/abbr>) market remains grounded in established topical and systemic therapies, although limitations in longterm disease control leave a sizable unmet need among topicalrefractory and moderatetosevere patients. Branded options are increasingly gaining momentum, with market growth driven by the uptake of <abbr title=\"interleukin\">IL<\/abbr>-13 \/ <abbr title=\"interleukin\">IL<\/abbr>-4 inhibitors, such as dupilumab (Sanofi\u2019s Dupixent), and stapokibart (Keymed Biosciences\u2019 Kangyueda), alongside oral <abbr data-abbreviation-entity=\"7988\" title=\"Janus kinase\">JAK<\/abbr> inhibitors, including abrocitinib (Pfizer\u2019s Cibinqo), upadacitinib (AbbVie\u2019s Rinvoq), and ivarmacitinib (Hengrui\u2019s Aisuda) for moderate to severe <abbr data-abbreviation-entity=\"7654\" title=\"atopic dermatitis\">AD<\/abbr>. For mild to moderate disease, crisaborole and benvitimod provide nonsteroidal topical options and is supported by approval in patients aged 2 years and older. Emerging therapiesnew <abbr title=\"interleukin\">IL<\/abbr>4 \/ <abbr title=\"interleukin\">IL<\/abbr>13 inhibitors, oral <abbr title=\"Janus kinase\">JAK<\/abbr>\u00a0\/\u00a0<abbr title=\"tyrosine kinase 2\">TYK2<\/abbr> inhibitors, <abbr title=\"interleukin\">IL<\/abbr>-13 inhibitors, OX40L inhibitors, and topical <abbr title=\"Janus kinase\">JAK<\/abbr> and <abbr title=\"phosphodiesterase\">PDE<\/abbr>-4 agentsare expected to broaden treatment choice across severity levels. In this report, we explore how unmet needs, pricing, coverage, regulatory reforms, <abbr title=\"National Reimbursement Drug List\">NRDL<\/abbr>, and <abbr title=\"value-based pricing\nvolume-based procurement\">VBP<\/abbr> developments may influence access and uptake in China, which will influence the launch and uptake of new therapies in this highly lucrative market.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What is the diagnosed prevalence of <abbr data-abbreviation-entity=\"7654\" title=\"atopic dermatitis\">AD<\/abbr> in China, and how are <abbr data-abbreviation-entity=\"7654\" title=\"atopic dermatitis\">AD<\/abbr> patients treated today?<\/li>\n<li>What are the key unmet needs in the management of <abbr data-abbreviation-entity=\"7654\" title=\"atopic dermatitis\">AD<\/abbr>?<\/li>\n<li>Who will be the leading player in the <abbr data-abbreviation-entity=\"7654\" title=\"atopic dermatitis\">AD<\/abbr> market by 2035?<\/li>\n<li>How will the <abbr data-abbreviation-entity=\"7654\" title=\"atopic dermatitis\">AD<\/abbr> therapy market evolve over the next 10 years??<\/li>\n<li>What are the key drivers and constraints in this market, and how will the market evolve over the forecast period?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p>China In-Depth offers comprehensive market intelligence with world-class epidemiology, insight into the China-specific market access landscape, current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Optimize your long-term disease and development strategy in China.<\/li>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<li>Understand current treatment paradigms, the complex access and reimbursement environment, and the current and future therapeutic landscape.<\/li>\n<li>Gauge the commercial outlook and impact of key market events.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-586311","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-china-in-depth","biopharma-geography-china","biopharma-geography-us","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/586311","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=586311"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}